Trial reportJournal of the American Heart Association2017
Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action.
Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.Circulation · 2020 · on this mapTrial
- Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action.Journal of the American Heart Association · 2017Trial
- Urine sodium concentration and diuretic responsiveness in dogs receiving orally administered loop diuretics for chronic congestive heart failure.Journal of veterinary internal medicine · 2026Article
- Mechanistic Differences between Torsemide and Furosemide.Journal of the American Society of Nephrology : JASN · 2025Article
- Article
- High Estimated 24-Hour Urinary Sodium Excretion Is Related to Symptomatic Knee Osteoarthritis: A Nationwide Cross-Sectional Population-Based Study.The journal of nutrition, health & aging · 2022Article
- An evaluation of torsemide in patients with heart failure and renal disease.Expert review of cardiovascular therapy · 2022Review
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.Frontiers in pharmacology · 2022Review
- Article
- Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.European heart journal · 2021Article
- Medical management of acute heart failure.Faculty reviews · 2021Review
- Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure.Hypertension (Dallas, Tex. : 1979) · 2020Review
- Diuretic Resistance in Heart Failure.Current heart failure reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundLoop diuretics are highly natriuretic but their short duration of action permits postdiuretic sodium retention, which limits salt loss unless dietary salt is severely restricted. We tested the hypothesis that a more prolonged duration of action would enhance salt loss. METHODS AND
resultsTen healthy participants were crossed over between 20 mg of oral immediate-release or extended-release (ER) torsemide while consuming a fixed diet with 300 mmol·d
conclusionsTorsemide ER prolongs urine drug levels, thereby increasing the time spent with effective drug concentrations, reduces postdiuretic Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.